REFERENCES
1. Anker SD, Butler J, Filippatos G, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med 2021;385:1451-61.
2. Committee Members. ACC/AHA joint committee members. 2022 AHA/ACC/HFSA guideline for the management of heart failure. J Card Fail 2022;28:e1-e167.
3. Upadhya B, Pisani B, Kitzman DW. Evolution of a geriatric syndrome: pathophysiology and treatment of heart failure with preserved ejection fraction. J Am Geriatr Soc 2017;65:2431-40.
4. Sanders NA, Supiano MA, Lewis EF, et al. The frailty syndrome and outcomes in the TOPCAT trial. Eur J Heart Fail 2018;20:1570-7.
5. Böhm M, Butler J, Filippatos G, et al. Empagliflozin improves outcomes in patients with heart failure and preserved ejection fraction irrespective of age. J Am Coll Cardiol 2022;80:1-18.
6. Butler J, Packer M, Filippatos G, et al. Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction. Eur Heart J 2022;43:416-26.
7. Butler J, Filippatos G, Jamal Siddiqi T, et al. Empagliflozin, Health Status, and Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial. Circulation 2022;145:184-93.
8. Goldfarb M, Sheppard R, Afilalo J. Prognostic and Therapeutic Implications of Frailty in Older Adults with Heart Failure. Curr Cardiol Rep 2015;17:92.
9. Filippatos G, Butler J, Farmakis D, et al. Empagliflozin for heart failure with preserved left ventricular ejection fraction with and without diabetes. Circulation 2022; doi: 10.1161/CIRCULATIONAHA.122.059785.
